Fed Circ panel reviews $235m GSK award over ‘skinny’ Teva generic
25-02-2021
Teva urges Fed Circuit to save skinny label law from ‘nullification’
03-12-2020
Ralf Liebhold / Shutterstock.com
Teva Pharmaceuticals has once again petitioned the US Court of Appeals for the Federal Circuit to reconsider its decision in a dispute over generic drug labelling which held that the drugmaker infringed GlaxoSmithKline’s (GSK) Coreg heart drug (Carvedilol).
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Teva Pharmaceuticals, Coreg, GlaxoSmithKline, Coreg, Federal Circuit, Carve-out, Skinny Label
